CN1193091C - 一种适于幼仓鼠肾细胞生长与维持的无血清培养基 - Google Patents
一种适于幼仓鼠肾细胞生长与维持的无血清培养基 Download PDFInfo
- Publication number
- CN1193091C CN1193091C CNB021106444A CN02110644A CN1193091C CN 1193091 C CN1193091 C CN 1193091C CN B021106444 A CNB021106444 A CN B021106444A CN 02110644 A CN02110644 A CN 02110644A CN 1193091 C CN1193091 C CN 1193091C
- Authority
- CN
- China
- Prior art keywords
- acid
- growth
- cell
- serum
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000699800 Cricetinae Species 0.000 title claims abstract description 8
- 230000012010 growth Effects 0.000 title claims abstract description 8
- 238000012423 maintenance Methods 0.000 title claims abstract 3
- 210000003292 kidney cell Anatomy 0.000 title claims description 5
- 239000012679 serum free medium Substances 0.000 claims abstract description 13
- 239000002609 medium Substances 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 102000004877 Insulin Human genes 0.000 claims description 5
- 108090001061 Insulin Proteins 0.000 claims description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- 229930195722 L-methionine Natural products 0.000 claims description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 3
- 101710134784 Agnoprotein Proteins 0.000 claims description 3
- 235000019743 Choline chloride Nutrition 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 3
- 239000007995 HEPES buffer Substances 0.000 claims description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 3
- 229930064664 L-arginine Natural products 0.000 claims description 3
- 235000014852 L-arginine Nutrition 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- 239000004395 L-leucine Substances 0.000 claims description 3
- 235000019454 L-leucine Nutrition 0.000 claims description 3
- 229930182821 L-proline Natural products 0.000 claims description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
- 229960005261 aspartic acid Drugs 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 229960003178 choline chloride Drugs 0.000 claims description 3
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 3
- 229960002989 glutamic acid Drugs 0.000 claims description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 3
- 229960002885 histidine Drugs 0.000 claims description 3
- 229960000367 inositol Drugs 0.000 claims description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- 229960003136 leucine Drugs 0.000 claims description 3
- 229960004488 linolenic acid Drugs 0.000 claims description 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 3
- 235000019136 lipoic acid Nutrition 0.000 claims description 3
- 229960004452 methionine Drugs 0.000 claims description 3
- 229960003966 nicotinamide Drugs 0.000 claims description 3
- 235000005152 nicotinamide Nutrition 0.000 claims description 3
- 239000011570 nicotinamide Substances 0.000 claims description 3
- 229960005190 phenylalanine Drugs 0.000 claims description 3
- 229960002429 proline Drugs 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 235000019192 riboflavin Nutrition 0.000 claims description 3
- 239000002151 riboflavin Substances 0.000 claims description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 3
- 229960001153 serine Drugs 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229960002663 thioctic acid Drugs 0.000 claims description 3
- 229960004799 tryptophan Drugs 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims description 2
- 235000021360 Myristic acid Nutrition 0.000 claims description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 229940114079 arachidonic acid Drugs 0.000 claims description 2
- 235000021342 arachidonic acid Nutrition 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- 235000021314 Palmitic acid Nutrition 0.000 claims 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 1
- 235000019766 L-Lysine Nutrition 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 229930182816 L-glutamine Natural products 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 229930003268 Vitamin C Natural products 0.000 claims 1
- 229960003767 alanine Drugs 0.000 claims 1
- 229940087168 alpha tocopherol Drugs 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 239000007640 basal medium Substances 0.000 claims 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 235000020778 linoleic acid Nutrition 0.000 claims 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims 1
- 229920001993 poloxamer 188 Polymers 0.000 claims 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims 1
- 229940054269 sodium pyruvate Drugs 0.000 claims 1
- 235000019157 thiamine Nutrition 0.000 claims 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims 1
- 229960003495 thiamine Drugs 0.000 claims 1
- 239000011721 thiamine Substances 0.000 claims 1
- 229960000984 tocofersolan Drugs 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 239000011726 vitamin B6 Substances 0.000 claims 1
- 239000002076 α-tocopherol Substances 0.000 claims 1
- 235000004835 α-tocopherol Nutrition 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 abstract description 3
- 238000000746 purification Methods 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 13
- 230000010261 cell growth Effects 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 102000002070 Transferrins Human genes 0.000 description 4
- 108010015865 Transferrins Proteins 0.000 description 4
- 150000002505 iron Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 235000019156 vitamin B Nutrition 0.000 description 4
- 239000011720 vitamin B Substances 0.000 description 4
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 229930003756 Vitamin B7 Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 229960004232 linoleic acid Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000011912 vitamin B7 Nutrition 0.000 description 2
- 239000011735 vitamin B7 Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 229910002554 Fe(NO3)3·9H2O Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229910018143 SeO3 Inorganic materials 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- -1 iron ion Chemical class 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开一种适于幼仓鼠肾(BHK)细胞高密度生长和维持的低蛋白无血清培养基,该培养基具有蛋白含量低、易于分离纯化及适于工业化生产的特点。
Description
技术领域
本发明涉及一种适于幼仓鼠肾细胞高密度生长和维持的低蛋白无血清培养基。
背景技术
幼仓鼠肾(BHK)细胞是一种能无限传代的哺乳动物细胞系,已被广泛用于生产疫苗、诊断试剂以及医药等生物技术产品。
BHK细胞通常在有血清培养基中培养,但血清的添加存在诸多不利:第一,血清非常昂贵,血清的费用占到培养基总费用的50%以上,致使生产成本大幅度提高;第二,批与批之间血清质量的差异,会影响细胞生长,最终影响产品质量;第三,血清易被支原体和外来试剂污染;第四,血清蛋白增加了下游培养产物分离、纯化的难度,这些缺点使得血清在细胞大规模培养中的使用受到限制,致使人们展开了无血清培养基的开发和应用研究。
近年来,无血清培养基的研究开发发展很快,已报道了多种能支持不同种类细胞生长的无血清培养,例如Casser et al.(In Vitro Cell.Devel.Biol.,88,21:588 1985)开发了一种能支持CHO细胞生长的培养基。该培养基以DMEM/F12(1∶1)为基础,添加了转铁蛋白、胰岛素以及亚硒酸钠,这就是现被广泛采用的(基础培养基+ITS)无血清培养基基础配方。美国专利U.S.592107公开了一种无血清培养基,该培养基含有高水平氨基酸,且添加了不同生长因子和微量元素,能支持CHO细胞高密度悬浮培养。但这些培养基多限于杂交瘤细胞和CHO细胞培养,且一般蛋白含量仍较高,通常可达几十毫克至几克,致使下游产物分离纯化的难度和成本增加。而涉及适于幼仓鼠肾细胞长期培养的低蛋白无血清培养基未见报道。
发明内容
本发明公开一种适于幼仓鼠肾(BHK)细胞高密度生长和维持的低蛋白无血清培养基,该培养基具有蛋白含量低、易于分离纯化及适于工业化生产的特点。
本发明的构思:
替代血清的补充因子种类很多,通常包括一些人类所必需的生长因子、激素、脂质、结合蛋白和多种微量元素等。为了有效的替代血清,支持细胞的高密度生长,本发明在基础培养基DMEM的基础上,添加了以下成分:
(1)转铁蛋白:一种结合铁的糖蛋白,与细胞表面专一受体作用,传递铁离子。
(2)胰岛素:胰岛β细胞分泌的多肽激素,能促进细胞生长。
(3)维生素:细胞的组成成分,是细胞生长所必需物质,细胞自身无法合成,须从外界摄取。
(4)微量元素:如Cu,Fe,Zn,Se,Co,Mo,Sn,Si,V,Mn等,主要起细胞生理过程调节。
(5)β-巯基乙醇:促进胱氨酸的吸收,可使谷胱甘肽处于还原状态,从而保护细胞免受过氧化氢的损害。
(6)脂质:包括一些脂肪酸和类脂,能促进细胞生长。例如:亚油酸、亚麻酸、油酸以及胆固醇等。
本发明的技术方案:
本发明所述的培养基为一种组合物,由基础培养基DMEM和以下添加物组成(添加剂量的单位如无特别说明均为mg/L):
L-天冬氨酸 0-20
L-谷氨酸 10-40
L-天冬酰胺 20-50
L-丝氨酸 0-10
L-谷氨酰胺 0-200
L-组氨酸 0-40
L-丙氨酸 0-40
L-精氨酸 50-150
L-蛋氨酸 10-50
L-色氨酸 0-50
L-苯丙氨酸 10-60
L-亮氨酸 20-60
L-赖氨酸 40-100
L-脯氨酸 10-30
NH4VO3 0.02-0.1
SnCl22H2O 1.00-2.00
Ba(C2H3O2)2 0.01-0.05
AgNO3 0.01-0.05
AlCl36H2O 0.3-1.5
3CdSO48H2O 0.001-0.005
CoCl26H2O 0.03-0.15
(NH4)6MoO244H2O 0.01-0.05
NiCl26H2O 0.1-0.5
Na2SeO3 0.01-0.05
KBr 0-0.0002
NaF 0-0.005
KI 0-0.0005
Na2SiO3 0.01-0.05
NaH2PO32H2O 0-100
FeSO47H2O 0.3-1.5
CuSO45H2O 0.001-0.005
ZnSO4 0.3-1.5
HEPES 1000-2500
胰岛素 2-20
转铁蛋白 2-20
丙酮酸钠 0-150
Primatone 1000-2500
类脂混合物* 0.1%-0.5%(v/v)
还原型谷胱甘肽 0.3-1.5
维生素C 3.5-13.5
维生素B6 0-0.06
维生素B12 0-0.68
氯化胆碱 0-5
肌醇 0-5
生物素(Biotin) 0-0.02
烟酰胺 0-2.02
核黄素 0-0.044
硫胺素 0-2.17
次黄嘌呤 0-2
硫辛酸 0-0.1
β-巯基乙醇 0-2.5
*:为GIBCO生产的化学成分确定脂质浓缩液(附组成,mg/L)
花生四稀酸 2
胆固醇 220
DL-醋酸α-生育酚 70
亚油酸 10
亚麻酸 10
豆蔻酸 10
油酸 10
棕榈稀酸 10
棕榈酸 10
Pluronic F-68 100000
硬脂酸 10
吐温80 2200
以上所述所有物质均为市售商品。
本发明所述的培养基采用常规的方法配制而成。
本发明所述的培养基使用方法为常规方法。
附图说明
图1为实施例1和对比例的试验结果图示。
其中:
●-采用无血清培养基的细胞密度(×105cells/mL)
▲-采用有血清培养基的细胞密度(×105cells/mL)
具体实施方法
下面将通过实施例对本发明作进一步的说明。
实施例1
按照下面的浓度配制无血清培养基(包括基础培养基DMEM成分,mg/L)然后在该培养基中接入BHK细胞(种子细胞为无血清培养细胞),接种密度为1.4×105cells/mL,培养4天(96小时)后,细胞密度可达到1.4×106cells/mL。
第一部分:氨基酸
L-胱氨酸二盐酸 63
L-天冬氨酸 8
L-谷氨酸 19
L-天冬酰胺 31
甘氨酸 30
L-丝氨酸 44
L-谷氨酰胺 688
L-组氨酸 63
L-丙氨酸 12
L-精氨酸 190
L-蛋氨酸 48
L-色氨酸 28
L-苯丙氨酸 86
二水L-酪氨酸二钠 104
L-亮氨酸 147
L-异亮氨酸 105
L-赖氨酸 209
L-脯氨酸 17
L-苏氨酸 95
L-缬氨酸 94
第二部分微量元素
CaCl2 200
Fe(NO3)3·9H2O 0.1
KCl 400
NCl 6400
NaHCO3 3700
NH4VO3 0.092
SnCl22H2O 1.556
Ba(C2H3O2)2 0.02
AgNO3 0.02
AlCl3·6H2O 0.99
3CdSO4·8H2O 0.003
CoCl2·6H2O 0.101
MnSO4·H2O 97.67
(NH4)6MoO24·4H2 O 0.033
NiCl2·6H2O 0.35
Na2SeO3 0.01
KBr 0.0001
NaF 0.0042
KI 0.0002
Na2SiO3 0.01
NaH2PO3·2H2O 193.00
FeSO4·7H2O 0.834
CuSO4·5H2O 0.0025
ZnSO4 0.863
第三部分:维生素和其它成分
HEPES 2000
胰岛素 5
转铁蛋白 5
酚红 15
D-葡萄糖 4500
丙酮酸钠 193
类脂混合物* 0.2%(v/v)
Primatone 1250
还原型谷胱甘肽 0.75
β-巯基乙醇 2.5
D-泛酸钙 4
维生素C 6.25
维生素B6 4.06
维生素B12 0.68
氯化胆碱 9
肌醇 12.2
叶酸 4.00
生物素(Biotin) 0.02
烟酰胺 6.02
核黄素 0.44
硫胺素 6.17
次黄嘌呤 2.00
硫辛酸 0.10
对比例
采用与实施例1相同的培养方法,所用的培养基为添加了5%(v/v)胎牛血清的DMEM培养基,细胞密度最大为1.2×106cells/mL。
由上述的实施例对比可发现,在本发明的无血清培养基中培养BHK细胞,细胞生长明显优于有血清的培养基,完全可替代血清用于BHK细胞培养。
Claims (1)
1、一种适于幼仓鼠肾细胞生长与维持的无血清培养基,其特征为所述的培养基为一种组合物,由基础培养基DMEM和以下添加物组成,添加剂量的单位如无特别说明均为mg/L:
L-天冬氨酸 0-20
L-谷氨酸 10-40
L-天冬酰胺 20-50
L-丝氨酸 0-10
L-谷氨酰胺 0-200
L-组氨酸 0-40
L-丙氨酸 0-40
L-精氨酸 50-150
L-蛋氨酸 10-50
L-色氨酸 0-50
L-苯丙氨酸 10-60
L-亮氨酸 20-60
L-赖氨酸 40-100
L-脯氨酸 10-30
NH4VO3 0.02-0.1
SnCl2 2H2O 1.00-2.00
Ba(C2H3O2)2 0.01-0.05
AgNO3 0.01-0.05
AlCl3 6H2O 0.3-1.5
3CdSO4 8H2O 0.001-0.005
CoCl2 6H2O 0.03-0.15
(NH4)6MoO24 4H2O 0.01-0.05
NiCl2 6H2O 0.1-0.5
Na2SeO3 0.01-0.05
KBr 0-0.0002
NaF 0-0.005
KI 0-0.0005
Na2SiO3 0.01-0.05
NaH2PO3 2H2O 0-100
FeSO4 7H2O 0.3-1.5
CuSO4 5H2O 0.001-0.005
ZnSO4 0.3-1.5
HEPES 1000-2500
胰岛素 2-20
转铁蛋白 2-20
丙酮酸钠 0-150
Primatone 1000-2500
类脂混合物* 0.1%-0.5%v/v
还原型谷胱甘肽 0.3-1.5
维生素C 3.5-13.5
维生素B6 0-0.06
维生素B12 0-0.68
氯化胆碱 0-5
肌醇 0-5
生物素(Biotin) 0-0.02
烟酰胺 0-2.02
核黄素 0-0.044
硫胺素 0-2.17
次黄嘌呤 0-2
硫辛酸 0-0.1
β-巯基乙醇 0-2.5
*:为GIBCO生产的化学成分确定脂质浓缩液:组成如下,单位为mg/L
花生四稀酸 2
胆固醇 220
DL-醋酸α-生育酚 70
亚油酸 10
亚麻酸 10
豆蔻酸 10
油酸 10
棕榈稀酸 10
棕榈酸 10
Pluronic F-68 100000
硬脂酸 10
吐温80 2200
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021106444A CN1193091C (zh) | 2002-01-25 | 2002-01-25 | 一种适于幼仓鼠肾细胞生长与维持的无血清培养基 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021106444A CN1193091C (zh) | 2002-01-25 | 2002-01-25 | 一种适于幼仓鼠肾细胞生长与维持的无血清培养基 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1362514A CN1362514A (zh) | 2002-08-07 |
CN1193091C true CN1193091C (zh) | 2005-03-16 |
Family
ID=4741177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021106444A Expired - Fee Related CN1193091C (zh) | 2002-01-25 | 2002-01-25 | 一种适于幼仓鼠肾细胞生长与维持的无血清培养基 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1193091C (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100364527C (zh) * | 2003-07-23 | 2008-01-30 | 华晨 | 一种维生素c与精氨酸的组合物及其应用 |
CN100432218C (zh) * | 2005-01-05 | 2008-11-12 | 上海尚优生物科技有限公司 | 无血清配方的动物细胞培养基胎牛血清替代剂 |
CN100348718C (zh) * | 2005-10-18 | 2007-11-14 | 中国人民解放军军事医学科学院生物工程研究所 | 一种支持hek293细胞贴附培养的无动物来源成分无血清培养基 |
PE20161326A1 (es) * | 2014-04-10 | 2016-12-11 | Bayer Healthcare Llc | Formulacion en polvo de medio de compuesto y metodo de preparacion de medio liquido para cultivo celular |
CN104894055B (zh) * | 2015-06-15 | 2018-07-17 | 成都金凯生物技术有限公司 | 一种优化的细胞培养基、细胞培养方法及其在制备蛋白和抗体中的应用 |
CN105087460A (zh) * | 2015-06-18 | 2015-11-25 | 上海源培生物科技股份有限公司 | 一种st细胞培养基 |
CN105087461A (zh) * | 2015-06-18 | 2015-11-25 | 上海源培生物科技股份有限公司 | 一种pk细胞培养基 |
CN111304169B (zh) * | 2019-12-03 | 2022-03-18 | 北京亚东生物制药有限公司 | 一种培养基添加物、含有该添加物的细胞培养基及其应用 |
-
2002
- 2002-01-25 CN CNB021106444A patent/CN1193091C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1362514A (zh) | 2002-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1908162A (zh) | 人胚胎肾(hek)293细胞无血清培养基 | |
CN101418330B (zh) | 适于nso细胞大规模培养及抗体生产的无蛋白培养基 | |
CA2797356C (en) | Improved cell culture medium | |
AU2011246504B2 (en) | Improved cell culture medium | |
CN102827804B (zh) | 适用于Vero细胞微载体悬浮放大培养的培养基及方法 | |
CN1187441C (zh) | 用于培养动物细胞的培养基和使用该培养基生产蛋白质的方法 | |
CN1193091C (zh) | 一种适于幼仓鼠肾细胞生长与维持的无血清培养基 | |
CN101974481A (zh) | 一种用于多种肾脏组织来源细胞生长的无血清培养基 | |
CN101048511A (zh) | 多肽的生产 | |
CN101052708A (zh) | 哺乳动物细胞的无血清细胞培养基 | |
EP0435911A1 (en) | CELL GROWING MEDIUM FOR INCREASED CELL GROWTH, FOR INCREASING LONGEVITY AND EXPRESSION OF THE PRODUCTS. | |
CN101061231A (zh) | TNFR-Ig融合蛋白的生产 | |
CN101048512A (zh) | 抗淀粉样β肽抗体的生产 | |
CN101057635A (zh) | 凡纳滨对虾低盐度秋冬季养殖生态饵料及其制备方法 | |
CN1205737A (zh) | 改良无限增殖化人类皮肤细胞系和用于其生产的新型无血清培育基 | |
CN1696283A (zh) | 一种适合中国仓鼠卵巢细胞培养的无血清培养基 | |
CN85107296A (zh) | 制备胃肠外营养溶液的方法 | |
CN104822821A (zh) | 用于优化灌流细胞培养系统的方法和系统 | |
CN1024809C (zh) | 用具有低乙酸形成能力的微生物生产有用物质的方法 | |
CN1238498C (zh) | 动物细胞无血清悬浮培养工艺过程控制参数的方法 | |
CN101061215A (zh) | 细胞的培养方法及其应用 | |
CN102021139A (zh) | 一种中国仓鼠卵巢细胞培养基及其制备方法和应用 | |
CN112063578B (zh) | 适应全悬浮细胞培养的培养基及其制备方法和应用 | |
US20050287666A1 (en) | Cell culture medium comprising transition metals or trace elements | |
CN1114619C (zh) | 小鼠杂交瘤株Hepama-1分泌的肝癌鼠源单克隆抗体的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050316 Termination date: 20140125 |